Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

Entries for July 2019

Up to $162.5M in upfront, cost sharing and milestone payments, and escalating royalties into the high teens assuming exercise of the option   SAN DIEGO, May 30, 2019 /PRNewswire/ — Inhibrx, Inc. (“Inhibrx”), a clinical-stage ...

[Read More...]

Dicerna begin the clinical development phase of an A1AT deficiency-associated liver disease program

[Read More...]